Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Metastatic prostate cancer has a 30% 5-year survival rate despite recent therapeutic advances. There is a need to improve the clinical understanding and treatment of this disease, particularly in the real-world setting and among patients who are under-represented in clinical trials. OBJECTIVE: We aimed to evaluate the characteristics and clinical outcomes of patients who received their first treatment for metastatic castration-resistant prostate cancer (mCRPC) in routine clinical practice, independent of treatment used, including subgroups with baseline cardiac disease, diabetes mellitus, or visceral metastases. PATIENTS AND METHODS: Prospective, noninterventional analysis of patient record data in the multicenter Prostate Cancer Registry (PCR) of men with mCRPC. The data were collected in 16 countries with the aim of recruiting more than 3000 patients between 2013 and 2016. The study end date was 9 July 2018. Data evaluated included baseline characteristics, treatment exposure, and efficacy outcomes [overall survival (OS) and time to progression (TTP)] of patients treated with abiraterone acetate plus prednisone or prednisolone (collectively, "abiraterone"), enzalutamide, or docetaxel. Descriptive outcomes are reported from the overall patient population and subgroups of patients with baseline cardiovascular disease, diabetes mellitus, or visceral metastases. The treatment effects for time to progression were compared for the overall patient population. RESULTS: The study enrollment period lasted 2.5 years, and each patient was followed for a maximum of 3 years. A total of 1874 patients in the PCR had not received previous mCRPC treatment at baseline, although they had received androgen-deprivation therapy. Prevalent co-morbidities included cardiovascular disease in 65.4% and diabetes mellitus in 17.4% of patients. Baseline characteristics suggested that patients with more advanced disease received docetaxel treatment. In the overall patient population, the median time to progression with abiraterone, enzalutamide, and docetaxel as first-line mCRPC therapy was 9.6, 10.3, and 7.6 months, respectively, and median OS was 27.1, 27.1, and 27.9 months, respectively. Outcomes in the subgroups of patients with cardiovascular disease or diabetes mellitus were similar to those of the whole population in the analysis. As expected, patients with visceral metastases had shorter TTP and OS than patients in the overall population. CONCLUSIONS: This analysis shows, for the first time, the effectiveness in parallel of first-line abiraterone, enzalutamide, and docetaxel in mCRPC, including in patients with co-morbidities such as cardiovascular disease or diabetes mellitus or in patients with visceral metastases. These real-world findings from the PCR provide meaningful information to help manage mCRPC, particularly in patients under-represented in clinical studies. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT02236637; registered September 2014.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 2×
“9 months with three-times-weekly docetaxel in patients with metastatic hormone-refractory prostate cancer in the phase 3 TAX 327 study [9].”
BackgroundResultEnzalutamide in Metastatic Prostate Cancer before Chemotherapy
Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405095 · Cited by 3,028 · cited 1×
“Median (range) age at baseline was 77 (50–94), 77 (59–91), and 71 (47–88) years, respectively (Supplementary Table S3A), which was older than the ages reported in recent registration studies [8, 9].”
ResultSelf-citationFerlay, J., Colombet, M., Soerjomataram, I., Dyba, T., Randi, G., Bettio, M., Gavin, A., Visser, O., & Bray, F. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.07.005 · Cited by 2,478 · cited 1×
“In Europe, 450,000 new cases of prostate cancer were diagnosed in 2018, and 107,000 deaths were reported [2].”
BackgroundPochon, S. (2005) · American Journal of Cancer · doi:10.2165/00024669-200504040-00008 · Cited by 1,424
Ryan, C. J., Smith, M. R., Fizazi, K., Saad, F., Mulders, P. F. A., Sternberg, C. N., Miller, K., Logothetis, C. J., Shore, N. D., Small, E. J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71205-7 · Cited by 1,369
Gillessen, S., Attard, G., Beer, T. M., Beltran, H., Bossi, A., Bristow, R., Carver, B., Castellano, D., Chung, B. H., Clarke, N., et al. (2018) · European Urology · doi:10.1016/j.eururo.2017.06.002 · Cited by 642 · cited 1×
“Expert opinion is helpful for treatment decisions in routine clinical practice [7]; however, there is a substantial need to improve the understanding and management of this disease—in particular, to avoid progression to disease states in which mortality rates are high and to assess patients outside of a clinical trial…”
BackgroundSelf-citationNuhn, P., De Bono, J. S., Fizazi, K., Freedland, S. J., Grilli, M., Kantoff, P. W., Sonpavde, G., Sternberg, C. N., Yegnasubramanian, S., & Antonarakis, E. S. (2019) · European Urology · doi:10.1016/j.eururo.2018.03.028 · Cited by 437
Oudard, S., Fizazi, K., Sengeløv, L., Daugaard, G., Saad, F., Hansen, S., Hjälm-Eriksson, M., Jassem, J., Thiery-Vuillemin, A., Caffo, O., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.1068 · Cited by 357 · cited 1×
“3 months for docetaxel [14], which is similar to our findings.”
ResultBasch, E., Loblaw, D. A., Oliver, T. K., Carducci, M., Chen, R. C., Frame, J. N., Garrels, K., Hotte, S., Kattan, M. W., Raghavan, D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8404 · Cited by 223
Gore, M. E., Szczylik, C., Porta, C., Bracarda, S., Bjarnason, G. A., Oudard, S., Lee, S.-H., Haanen, J., Castellano, D., Vrdoljak, E., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.196 · Cited by 187
Cited by
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer
Freedland, S. J., de Almeida Luz, M., De Giorgi, U., Gleave, M., Gotto, G. T., Pieczonka, C. M., Haas, G. P., Kim, C.-S., Ramirez-Backhaus, M., Rannikko, A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303974 · Cited by 319
Ashrafizadeh, M., Dai, J., Torabian, P., Nabavi, N., Aref, A. R., Aljabali, A. A. A., Tambuwala, M. M., & Zhu, M. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05236-w · Cited by 95
Petrylak, D. P., Ratta, R., Matsubara, N., Korbenfeld, E. P., Gafanov, R. A., Mourey, L., Todenhöfer, T., Gurney, H., Kramer, G., Bergman, A. M., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-01283 · Cited by 83
Self-citationAgarwal, N., Azad, A., Carles, J., Fay, A. P., Matsubara, N., Szczylik, C. A., Giorgi, U. D., Joung, J. Y., Fong, P. C. C., Voog, É., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00684-1 · Cited by 74
Mao, S., Zhang, W., Yang, F., Guo, Y., Wang, H., Wu, Y., Wang, R., Maskey, N., Zheng, Z., Cheng, L., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02138-8 · Cited by 48
Metadata
- Authors
- Chowdhury, S., Bjartell, A., Lumen, N., Maroto, P., Paiss, T., Gomez-Veiga, F., Birtle, A., Kramer, G., Kalinka, E., Spaëth, D., Feyerabend, S., Matveev, V., Lefresne, F., Lukac, M., Wapenaar, R., & Costa, L.
- Affiliations
- Sarah Cannon Research Institute (GB)
- Skåne University Hospital (SE)
- Ghent University Hospital (BE)
- Universitat Autònoma de Barcelona (ES)
- Royal Preston Hospital (GB)
- Medical University of Vienna (AT)
- Praxis für Humangenetik Tübingen (DE)
- Russian Cancer Research Center NN Blokhin (RU)
- Janssen (Belgium) (BE)
- Corresponding author
- Chowdhury, Simon
- ORCID
- Venue
- Targeted Oncology
- Published
- 2020-06
- Volume
- 15
- Issue
- 3
- Pages
- 301-315
- ISSN
- 1776-2596 (ISSN-L)
- 1776-260X
- PMC
- PMC7283204
- OpenAlex
- W3033684926
- Cited by
- 86
- References
- 11
- Citations by year
- 2026: 15 · 2025: 14 · 2024: 18 · 2023: 10 · 2022: 13 · 2021: 14 · 2020: 2
- FWCI
- 5.92
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor, 3 d)
- Locations
- Targeted Oncology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, cc-by)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by-nc)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
- Funders
- Janssen EMEA
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Keywords
- metastatic castration-resistant prostate cancer, first-line therapy, abiraterone, enzalutamide, docetaxel, overall survival, time to progression, cardiovascular disease, diabetes mellitus, visceral metastases, real-world outcomes, prostate cancer registry, androgen deprivation therapy, comorbidities
- MeSH terms
- Adult, Aged, Aged, 80 and over, Humans, Male, Middle Aged, Neoplasm Metastasis, Prospective Studies, Registries, Survival Rate, Treatment Outcome, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry. https://app.cochat.ai/papers/10.1007/s11523-020-00720-2
- The paper
- Chowdhury, S., Bjartell, A., Lumen, N., Maroto, P., Paiss, T., Gomez-Veiga, F., Birtle, A., Kramer, G., Kalinka, E., Spaëth, D., Feyerabend, S., Matveev, V., Lefresne, F., Lukac, M., Wapenaar, R., & Costa, L. (2020). Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry. Targeted Oncology. https://doi.org/10.1007/s11523-020-00720-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.